Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Open-Label, Multicenter Study of SNS-595 Injection in Patients With Platinum-Resistant Ovarian Cancer

NCT00408603 is registered in ClinicalTrials.gov with Sunesis Pharmaceuticals as lead sponsor.

NCT NCT00408603
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00408603 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Open-Label, Multicenter Study of SNS-595 Injection in Patients With Platinum-Resistant Ovarian Cancer
Lead sponsor
Sunesis Pharmaceuticals
Phase
Phase 2
Overall status
Completed
Start date
December 20, 2006
Completion date
June 9, 2010
Enrollment
183 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

epithelial ovarian cancer